Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an update.
Shanghai Junshi Biosciences Co., Ltd. has announced the proposed adoption of the 2025 H Share Option Incentive Scheme and the 2025 A Share Option Incentive Scheme, which are subject to shareholder approval. These schemes aim to attract, incentivize, and retain talent by aligning participants’ interests with those of the company and its shareholders. The proposed grants include 13,210,000 H Share Options to several executive directors and 8,000,000 A Share Options to a substantial shareholder, Mr. Xiong. The adoption of these schemes is expected to contribute to the company’s long-term growth and enhance shareholder value.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a joint stock company incorporated in China, operating in the biotechnology industry. The company focuses on developing innovative therapies, primarily through biosciences, to address various medical needs.
Average Trading Volume: 13,805,868
Technical Sentiment Signal: Buy
Current Market Cap: HK$45.72B
For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.